[1]CurrentPatentAssignee:HANGZHOUPUSHAIPHARMACEUTICALTECHNOLOGYCOLTD(unclear)-CN105384730,2016,ALocationinpatent:Paragraph0075;0076
[2]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-WO2006/117359,2006,A1Locationinpatent:Page/Pagecolumn17
[3]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-US2007/249544,2007,A1Locationinpatent:Page/Pagecolumn6
[4]CurrentPatentAssignee:ZYDUSLIFESCIENCESLTD-US2017/247356,2017,A1Locationinpatent:Paragraph0170;0193;0194
[5]CurrentPatentAssignee:DRREDDY'SLABORATORIESLIMITED-WO2017/203457,2017,A1Locationinpatent:Page/Pagecolumn42-44
[1]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-US2006/258749,2006,A1Locationinpatent:Page/Pagecolumn29-30
[2]CurrentPatentAssignee:LUPINLIMITED-WO2017/141202,2017,A1
[3]CurrentPatentAssignee:HANSOHPHARMACEUTICALGROUPCOLTD-CN106336403,2017,A
108-24-7
[1]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-WO2007/93610,2007,A1Locationinpatent:Page/Pagecolumn42
[1]CurrentPatentAssignee:YANGTZERIVERPHARMACEUTICALGROUPCOLTD-CN110407891,2019,ALocationinpatent:Paragraph0043-0048
[2]CurrentPatentAssignee:JIANGSUCOLLEGEOFENGINEERINGANDTECHNOLOGY-CN107652276,2018,ALocationinpatent:Paragraph0015;0021
[3]CurrentPatentAssignee:JIANGSUCOLLEGEOFENGINEERINGANDTECHNOLOGY-CN107652277,2018,ALocationinpatent:Paragraph0022
[4]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-WO2011/39107,2011,A1Locationinpatent:Page/Pagecolumn21-23
[5]CurrentPatentAssignee:JIANGSUCOLLEGEOFENGINEERINGANDTECHNOLOGY-CN107652278,2018,ALocationinpatent:Paragraph0022
[6]CurrentPatentAssignee:BEIJINGWINSUNNYPHARMACEUTICAL-CN105481915,2016,ALocationinpatent:Paragraph0035;0036
[7]Wang,Xiao-Jun;Zhang,Li;Byrne,Denis;Nummy,Larry;Weber,Dirk;Krishnamurthy,Dhileep;Yee,Nathan;Senanayake,ChrisH.[OrganicLetters,2014,vol.16,#16,p.4090-4093]
[8]CurrentPatentAssignee:ANHUIJIUHUAHUAYUANPHARMACEUTICAL-CN106632288,2017,ALocationinpatent:Paragraph0076;0077;0078;0079;0080
[9]Peng,Peng;Zhao,Chuanmeng;Yang,Jiangtao;Liu,Xiao;Yu,Jun;Zhang,Fuli[OrganicPreparationsandProceduresInternational,2022,vol.54,#3,p.203-219]
[10]CurrentPatentAssignee:THEKALYANIGROUP-WO2021/250565,2021,A1Locationinpatent:Page/Pagecolumn4;9-11
[11]CurrentPatentAssignee:YANGTZERIVERPHARMACEUTICALGROUPCOLTD-CN107163033,2017,ALocationinpatent:Paragraph0035;0036
[12]CurrentPatentAssignee:SHANGHAIFOSUNPHARMACEUTICAL(GROUP)CO.,LTD.-CN109988161,2019,ALocationinpatent:Paragraph0067-0073
[13]CurrentPatentAssignee:JIANGSUDEYUANPHARMCOLTD-CN114380775,2022,ALocationinpatent:Paragraph0061-0068
[1]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-US2011/237789,2011,A1
[2]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-US2011/237526,2011,A1
[3]CurrentPatentAssignee:JIANGSUCOLLEGEOFENGINEERINGANDTECHNOLOGY-CN107652276,2018,A
[4]CurrentPatentAssignee:JIANGSUCOLLEGEOFENGINEERINGANDTECHNOLOGY-CN107652277,2018,A
Title: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Journal: The New England journal of medicine 20151126
Title: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Journal: Clinical pharmacokinetics 20150701
Title: Empagliflozin for the treatment of type 2 diabetes.
Journal: Expert opinion on pharmacotherapy 20141101
Title: Empagliflozin (Jardiance) for diabetes.
Journal: The Medical letter on drugs and therapeutics 20141013
Title: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Journal: Diabetes, obesity & metabolism 20141001
Title: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Journal: Diabetes care 20140601
Title: Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
Journal: Expert opinion on investigational drugs 20140601
Title: Empagliflozin for the treatment of Type 2 diabetes.
Journal: Expert review of clinical pharmacology 20140501
Title: Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Journal: Drugs in context 20140101
Title: Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin.
Journal: International journal of toxicology 20140101
Title: Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Journal: Advances in therapy 20121001
Title: Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
Journal: Diabetes, obesity & metabolism 20120701
Title: A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Journal: Annals of medicine 20120601
Title: [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Journal: Orvosi hetilap 20120506
Title: Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Journal: Diabetes, obesity & metabolism 20120101
Title: Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
Journal: Diabetes, obesity & metabolism 20120101
Title: Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.
Journal: The Journal of clinical endocrinology and metabolism 20100101
Title: From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.
Journal: Current medical research and opinion 20090301
Title: Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080901
Title: Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90.
Title: Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11(1):e0147391.
Title: Nikole J.ByrneBSc, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC Basic Transl Sci. 2017 Aug;2(4):347-354.
Title: Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943.
